New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?

New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?

Psoriasis and psoriatic arthritis (PsA) development is sustained by tumor necrosis factor (TNF)α, interleukin (IL)17, and IL23; hence, biologics targeting those cytokines represent useful therapeutic weapons for both conditions. Nevertheless, biologics strongly reduce PsA risk; several studies repor...

Full description

Bibliographic Details
Main Authors: Matteo Megna, Sonia Sofia Ocampo-Garza, Luca Potestio, Giuseppina Fontanella, Lucia Gallo, Sara Cacciapuoti, Angelo Ruggiero, Gabriella Fabbrocini
Format: Article
Language:English
Published: MDPI AG 2021-10-01
Series:Biomedicines
Subjects:
psoriasis
psoriatic arthritis
biologic therapies
paradoxical reaction
anti-TNF
anti-IL12/23
Online Access:https://www.mdpi.com/2227-9059/9/10/1482

Internet

https://www.mdpi.com/2227-9059/9/10/1482

Similar Items